M&A Deal Summary

Celgene Acquires Juno Therapeutics

On January 22, 2018, Celgene acquired life science company Juno Therapeutics for 9.0B USD

Acquisition Highlights
  • This is Celgene’s 12th transaction in the Life Science sector.
  • This is Celgene’s largest (disclosed) transaction.
  • This is Celgene’s 12th transaction in the United States.
  • This is Celgene’s 1st transaction in Washington.

M&A Deal Summary
Date 2018-01-22
Target Juno Therapeutics
Sector Life Science
Buyer(s) Celgene
Deal Type Add-on Acquisition
Deal Value 9.0B USD
Advisor(s) Morgan Stanley (Financial)

Target

Juno Therapeutics

Seattle, Washington, United States
Juno Therapeutics, Inc. is a biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Juno Therapeutics was founded in 2013 and is based in Seattle, Washington.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Celgene

Summit, New Jersey, United States
Category Company
Founded 1980
Sector Life Science
Employees6,971
Revenue 13.0B USD (2017)
DESCRIPTION

Celgene Corp. is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Celgene Corp. was established in 1980 and is headquartered in Summit, New Jersey.

DEAL STATS #
Overall 15 of 15
Sector (Life Science) 12 of 12
Type (Add-on Acquisition) 13 of 13
State (Washington) 1 of 1
Country (United States) 12 of 12
Year (2018) 2 of 2
Size (of disclosed) 1 of 12
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-01-07 Impact Biomedicines

San Diego, California, United States

Impact Biomedicines, Inc. is a developer of life changing treatments for patients with complex cancers. Impact Biomedicines was founded in 2016 and is based in San Diego, United States.

Buy $1.1B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-08-26 Otezla

United States

Otezla is a treatment in the post-topical, pre-biologic segment in its approved indications. Otezla is currently approved for three indications in the U.S.—the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy; adult patients with active psoriatic arthritis; and adult patients with oral ulcers associated with Behçet's Disease.

Sell $13.4B
Mergr

Product

Company

Legal